Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 2
2012 3
2013 2
2014 4
2015 4
2016 1
2017 4
2018 2
2019 1
2020 1
2021 2
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

26 results
Results by year
Filters applied: . Clear all
Page 1
Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer.
Ghonim MA, Ibba SV, Tarhuni AF, Errami Y, Luu HH, Dean MJ, El-Bahrawy AH, Wyczechowska D, Benslimane IA, Del Valle L, Al-Khami AA, Ochoa AC, Boulares AH. Ghonim MA, et al. Among authors: al khami aa. J Immunother Cancer. 2021 Jan;9(1):e001643. doi: 10.1136/jitc-2020-001643. J Immunother Cancer. 2021. PMID: 33495297 Free PMC article.
Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies.
Hossain F, Al-Khami AA, Wyczechowska D, Hernandez C, Zheng L, Reiss K, Valle LD, Trillo-Tinoco J, Maj T, Zou W, Rodriguez PC, Ochoa AC. Hossain F, et al. Among authors: al khami aa. Cancer Immunol Res. 2015 Nov;3(11):1236-47. doi: 10.1158/2326-6066.CIR-15-0036. Epub 2015 May 29. Cancer Immunol Res. 2015. PMID: 26025381 Free PMC article.
Combinatorial immunotherapy induces tumor-infiltrating CD8+ T cells with distinct functional, migratory, and stem-like properties.
Van Braeckel-Budimir N, Dolina JS, Wei J, Wang X, Chen SH, Santiago P, Tu G, Micci L, Al-Khami AA, Pfister S, Ram S, Sundar P, Thomas G, Long H, Yang W, Potluri S, Salek-Ardakani S. Van Braeckel-Budimir N, et al. Among authors: al khami aa. J Immunother Cancer. 2021 Dec;9(12):e003614. doi: 10.1136/jitc-2021-003614. J Immunother Cancer. 2021. PMID: 34903555 Free PMC article.
A novel patient-derived xenograft model for claudin-low triple-negative breast cancer.
Matossian MD, Burks HE, Bowles AC, Elliott S, Hoang VT, Sabol RA, Pashos NC, O'Donnell B, Miller KS, Wahba BM, Bunnell BA, Moroz K, Zea AH, Jones SD, Ochoa AC, Al-Khami AA, Hossain F, Riker AI, Rhodes LV, Martin EC, Miele L, Burow ME, Collins-Burow BM. Matossian MD, et al. Among authors: al khami aa. Breast Cancer Res Treat. 2018 Jun;169(2):381-390. doi: 10.1007/s10549-018-4685-2. Epub 2018 Feb 1. Breast Cancer Res Treat. 2018. PMID: 29392581 Free PMC article.
Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody.
Al-Khami AA, Youssef S, Abdiche Y, Nguyen H, Chou J, Kimberlin CR, Chin SM, Kamperschroer C, Jessen B, Kern B, Budimir N, Dillon CP, Xu A, Clark JD, Chou J, Kraynov E, Rajpal A, Lin JC, Salek-Ardakani S. Al-Khami AA, et al. Mol Cancer Ther. 2020 Oct;19(10):2105-2116. doi: 10.1158/1535-7163.MCT-20-0093. Epub 2020 Aug 26. Mol Cancer Ther. 2020. PMID: 32847983
26 results